Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.85 |
| ▸ | RAB9A | P51151 | 5/20 | 0.85 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.83 |
| ▸ | CASP3 | P42574 | 1/20 | 0.77 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.77 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.77 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.77 |
| ▸ | MITF | O75030 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6069177 | 0.92 | NPC1 (1.00) | NPC1RAB9ANR4A2CASP3SENP8 | |
| SCHEMBL11409473 | 0.91 | NR4A2 (1.00) | NPC1RAB9ANR4A2CASP3SENP8 | |
| SCHEMBL2488636 | 0.91 | NR4A2 (1.00) | NPC1RAB9ANR4A2CASP3SENP8 | |
| SCHEMBL6068962 | 0.89 | NR4A2 (0.80) | NPC1RAB9ANR4A2CASP3SENP8 | |
| SCHEMBL3663640 | 0.88 | NPC1 (1.00) | NPC1RAB9ANR4A2CASP3SENP8 | |
| SCHEMBL5532304 | 0.85 | NPC1 (0.95) | NPC1RAB9ANR4A2CASP3SENP8 | |
| SCHEMBL5534395 | 0.84 | NR4A2 (0.76) | NPC1RAB9ANR4A2CASP3SENP8 | |
| SCHEMBL2485014 | 0.84 | NR4A2 (0.83) | NPC1RAB9ANR4A2CASP3SENP8 | |
| SCHEMBL2484780 | 0.84 | NR4A2 (1.00) | NPC1RAB9ANR4A2CASP3SENP8 | |
| SCHEMBL6069168 | 0.84 | NPC1 (0.74) | NPC1RAB9ANR4A2CASP3SENP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1418912-B1 | ISOXAZOLOPYRIDINONES | NOVARTIS AG (CH) | 2007-02-28 | — | — | EP | claimed |
| EP-1418912-B1 | ISOXAZOLOPYRIDINONES | NOVARTIS AG (CH) | 2007-02-28 | — | — | EP | disclosed |
| US-7087756-B2 | Isoxazolopyridinones | NOVARTIS AG (CH) | 2006-08-08 | — | — | US | disclosed |
| US-20040248893-A1 | Isoxazolopyridinones | NOVARTIS AG (CH) | 2004-12-09 | — | — | US | disclosed |
| EP-1418912-A2 | ISOXAZOLOPYRIDINONES | Novartis AG (CH) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003015780-A2 | ISOXAZOLOPYRIDINONES AND USE THEREOF IN THE TREATMENT OF PARKINSON'S DISEASE | NOVARTIS AG (CH) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248893-A1 | Isoxazolopyridinones | XDH, NPY1R, TBXA2R | NPC1 3047/4885RAB9A 2041/4885NR4A2 2718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.